“回流药”花样翻新，治理要顺势应变

Core Viewpoint - The illegal resale of medical insurance drugs has formed a black industrial chain, posing health risks to patients and severely undermining the security of the national medical insurance fund [1][2][3]. Group 1: Traditional Practices and Current Trends - Traditional practices involved drug dealers directly purchasing reimbursed drugs from patients at slightly higher than the purchase price but significantly lower than market price, exploiting patients' lack of understanding of medical insurance policies [1]. - Recent trends show that drug dealers have developed a complete chain from inducing patients to acquire drugs, to multi-level transactions, ultimately leading to market entry, often using online platforms and social media to gain patients' trust [2]. Group 2: Emerging Risks and Regulatory Challenges - The rise of internet healthcare and online drug purchasing may lead to new illegal drug resale methods, such as using fake accounts and orders to obtain medical insurance reimbursements [3]. - The expansion of medical insurance cross-regional settlements increases the risk of illegal drug resales across regions, necessitating enhanced regulatory measures [3]. Group 3: Regulatory Recommendations - To combat the growing issue of cross-regional drug resales, it is recommended that various departments establish information-sharing and joint law enforcement mechanisms to break down information barriers [3]. - Utilizing big data and artificial intelligence for real-time monitoring and analysis of medical insurance reimbursement and drug circulation data is essential to detect anomalies and improve regulatory precision [3].